ADVB NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Advanced Biomed Inc. Common Stock · Healthcare · Diagnostics & Research

Open interactive chart View report data
Latest close 8.00 USD
-57.9% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 42.7% above the Trend Line and sits at 21.3% of its 52-week range. The latest completed week returned -57.9%, after a 60.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 58/100. Near-term considerations: volume confirmation is below normal.

Setup score 48 out of 100
Latest Close 8.00 USD 31 Jul 2026
1W Return -57.9% latest completed week
4W Return 60.3% short-term follow-through
12W Return 29.2% quarterly tape
Trend Breadth 3.8% 2 of 52 weeks active
Volume Ratio 0.1x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Next-week expectancy is positive at 77.78% based on similar historical setup states.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -57.9% Latest completed week; four-week move 60.3%. Indicator stack 9/71 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 77.78% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 58/100 53 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 42.7% above the Trend Line and sits at 21.3% of its 52-week range. The latest completed week returned -57.9%, after a 60.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.1x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2512-week average 0.21

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership2/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.25Current proprietary activity-pressure read.
Buy signals2Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 60.3% over four weeks, 29.2% over 12 weeks, and -6.4% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W-57.9%
4W60.3%
12W29.2%
26W32.5%
52W-6.4%
Active trend streak2 weeks
Active weeks in one year2
Trend breadth3.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.15Latest activity-pressure read.
Pressure change0.5%Four-week change in activity pressure.
Leadership6.33Latest relative-leadership reading.
RS change116.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength74/100Blend of value, momentum, and quality. Underlying universe rank 27; rank 1 is best.
Value62/100Relative valuation strength. Underlying universe rank 39; rank 1 is best.
Quality60/100Profitability and accounting quality. Underlying universe rank 41; rank 1 is best.
Momentum62/100Medium-term price momentum. Underlying universe rank 39; rank 1 is best.
Growth62/100Revenue and earnings growth. Underlying universe rank 39; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-0.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-1.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
22.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment58/100

Weighted news tone is neutral across 53 relevant articles.

18 positive · 31 neutral · 4 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-67.0%Distance below the 52-week high.
13-week volatility78.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+277.3%Week of 24 Jul.
Worst week-57.9%Week of 31 Jul.
Latest week-57.9%Week of 31 Jul.

Shape of recent returns

Strong gains11
Modest gains4
Flat weeks0
Modest losses1
Sharp losses10
Recent vol78.0%13-week weekly-return volatility.
Base vol41.7%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew22.2% / -13.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape41/100

Trend, activity pressure, participation, and risk combine to a 41/100 tape read.

 Indicator analysis41/100

Latest 12-week confirmation: trend 2/12, activity pressure 12/12, relative leadership 2/12.

Activity pressure 0.25; No reversal markers Next-Week ExpectancyPositive 77.78%

Next-week expectancy is positive with a 77.78% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors64/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 46 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Sentiment58/100

Weighted news tone is neutral across 53 relevant articles.

Advanced Biomed Company Profile & Introduction Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20268.00 USD-57.9%5.61 USD14.70 USD1.156.331.1MOn
24 Jul 202618.98 USD277.3%5.54 USD14.79 USD1.11151.94100.4MOn
17 Jul 20265.03 USD-2.5%5.15 USD14.73 USD0.87-33.132.8MOff
10 Jul 20265.16 USD3.4%5.23 USD14.87 USD1.01-36.2294.5KOff
3 Jul 20264.99 USD11.1%5.32 USD15.01 USD1.15-39.3195.1KOff
26 Jun 20264.49 USD-12.0%5.41 USD15.15 USD1.27-46.4939.7KOff
19 Jun 20265.10 USD13.3%5.54 USD15.31 USD1.49-43.74156.1KOff
12 Jun 20264.50 USD7.9%5.62 USD15.46 USD1.51-50.55193.4KOff
5 Jun 20264.17 USD-16.8%5.76 USD15.63 USD1.56-55.1996.9KOff
29 May 20265.01 USD26.8%5.89 USD15.80 USD1.68-50.72319.0KOff
22 May 20263.95 USD-10.2%6.04 USD15.97 USD1.62-61.7976.4KOff
15 May 20264.40 USD-28.9%6.21 USD16.16 USD1.60-59.0797.9KOff
8 May 20266.19 USD17.5%6.38 USD16.35 USD1.40-45.555.1MOff
1 May 20265.27 USD-8.0%6.50 USD16.52 USD1.23-52.821.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.